ING Groep NV Has $7 Million Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

ING Groep NV lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 426.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,882 shares of the biopharmaceutical company’s stock after purchasing an additional 40,410 shares during the period. ING Groep NV’s holdings in Alexion Pharmaceuticals were worth $6,998,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of ALXN. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals during the second quarter worth about $111,000. Huntington National Bank boosted its holdings in shares of Alexion Pharmaceuticals by 1,084.6% during the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 987 shares during the period. Penserra Capital Management LLC boosted its holdings in shares of Alexion Pharmaceuticals by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 144 shares during the period. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $156,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Alexion Pharmaceuticals during the second quarter worth about $160,000. Institutional investors own 95.80% of the company’s stock.

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 target price for the company. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. Leerink Swann restated an “outperform” rating and issued a $182.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $154.01.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded down $0.45 during midday trading on Thursday, hitting $107.60. 1,800,600 shares of the company’s stock were exchanged, compared to its average volume of 2,294,205. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market capitalization of $23,940.00, a P/E ratio of 22.10, a price-to-earnings-growth ratio of 1.18 and a beta of 1.22. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter last year, the firm earned $1.23 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current year.

WARNING: “ING Groep NV Has $7 Million Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/23/ing-groep-nv-has-7-million-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the transaction, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock valued at $2,337,251 in the last ninety days. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply